Scott A. Samuels

Member vCard


  • George Mason University (JD, 1996)
  • Cornell University (BA, 1992)

Bar Admissions

  • Massachusetts
  • Pennsylvania

Scott’s practice focuses on corporate and securities law matters, primarily for life sciences and technology companies. Scott has represented both private and public companies, underwriters, venture capital funds, angel investors and other parties in a broad range of transactions, including the formation and growth of start-up and emerging companies, private and public offerings, and mergers and acquisitions.

As it relates to his focus on start-up and earlier stage companies, Scott advises on a full spectrum of corporate matters, including formation, financing, equity compensation, contracts, and employee/consultant agreements, and coordinates with the firm's specialists in IP, employment, immigration, and other areas as needed. Scott also devotes a significant portion of his practice to counseling later-stage companies on IPO and M&A exits, as well as public companies on SEC disclosure and corporate governance matters, including Sarbanes-Oxley, the JOBS Act, and stock exchange regulations.

Before joining Mintz Levin, Scott served as a law clerk for a federal judge in the US District Court, Eastern District of Pennsylvania. During law school, he interned for the Chairman of the Federal Communications Commission and in the telecommunications section of the Antitrust Division of the US Department of Justice, and he was editor-in-chief of the George Mason Law Review.

Representative Matters

Venture Capital & Other Financings

  • Represented Intarcia Therapeutics, Inc. in its $200 million equity financing.
  • Represented Mass Medical Angels (MA2) in Series A financings for InfoBionic, Sabik Medical, Sialix, ZetrOZ, and other portfolio investments.
  • Represented Angiochem, Inc. in its license transaction with Geron Corporation (Nasdaq: GERN), including the private placement by Geron of $27.5 million of shares of common stock.
  • Represented Archemix Corp. in its Series B, C, and D financings and in general corporate matters.
  • Represented TwistDx, Inc., Genetix Pharmaceuticals, Inc., Performance Plants, Inc., Senex Biotechnology, Inc. and other private companies in various equity and convertible debt financings.
  • Represented MPM Capital and other investors in a $45 million Series A financing of Alinea Pharmaceuticals, Inc.
  • Represented Aureon Laboratories, Inc. in its $20 million Series B financing.

Public & Private Offerings for Public Companies

  • Represented Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) in its $60 million private financing, reverse merger, and $115 million initial public offering.
  • Represented Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) in its $86 million initial public offering.
  • Represented ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) in its $258 million follow-on public offering and other public offerings.
  • Represented BG Medicine, Inc. (Nasdaq: BGMD) in its $40 million initial public offering.
  • Represented Synta Pharmaceuticals Corp. (Nasdaq: SNTA) in its $35 million equity line facility with Azimuth Opportunity Ltd.
  • Represented Alphatec Holdings, Inc. (Nasdaq: ATEC) in its $92 million follow-on and secondary public offering.
  • Represented Azure Dynamics Corporation (TSX: AZD) in various US private placements conducted contemporaneously with Canadian public offerings. 

Mergers & Acquisitions

  • Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $270 million acquisition of Crescendo Bioscience, Inc., including an earlier $25 million strategic debt investment and option to acquire, and its $80 million acquisition of Rules-Based Medicine, Inc.
  • Represented Boston Biomedical, Inc. in its up to $2.6 billion acquisition by Dainippon Sumitomo Pharma Co., Ltd. (Tokyo Stock Exchange).
  • Represented Pluromed, Inc. in its acquisition by Sanofi (NYSE: SNY) (undisclosed amount).
  • Represented FoldRx Pharmaceuticals, Inc. in its acquisition by Pfizer, Inc. (NYSE: PFE) (undisclosed amount).
  • Represented ION Torrent Systems Incorporated in its $725 million acquisition by Life Technologies Corporation (Nasdaq: LIFE).
  • Represented Alphatec Holdings, Inc. (Nasdaq: ATEC) in its acquisition of Scient’x Groupe SAS (all stock consideration).
  • Represented Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its $300+ million (cash and stock) acquisition of ViroChem Pharma Inc.
  • Represented the MacGregor Group, Inc. in its $230 million acquisition by Investment Technology Group, Inc. (NYSE: ITG). 

Recognitions & Awards

  • Recommended by The Legal 500 United States for Healthcare: Life Sciences (2013)
  • Massachusetts Super Lawyers: Rising Star – Securities & Corporate Finance (2005 – 2007)